🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Valemetostat Tosylate, Valemetostat Tosylate

    The George Institute

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    phase 2 small molecule active

    1 trial

  2. Vebreltinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable MET-altered Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Vectibix 20 mg/ml concentrate for solution for infusion, VALPROIC ACID, VALPROIC ACID, Irinotecan Accord 20 mg/ml concentrato per soluzione perinfusione

    Fondazione Telethon ETS

    RAS/BRAF wild-type metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  4. Verzenios 50 mg film-coated tablets

    Ningbo Cancer Hospital

    High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.

    phase 2 small molecule active

    1 trial

  5. Verzenios 50 mg film-coated tablets, TAMOXIFEN

    Eli Lilly Co.

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer of Biliary Duct

    phase 2 small molecule active

    1 trial

  7. Vitamin D

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  8. Volrustomig

    AstraZeneca

    Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)

    phase 2 mab active

    1 trial

  9. WBRT

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 other active

    1 trial

  10. WSD0922-FU, WSD0922-FU

    Alphapharm Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. Watchful waiting, RO7198457 (autogene cevumeran)

    BioNTech SE

    Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer

    phase 2 small molecule active

    1 trial

  12. XB2001 or Placebo

    XBiotech Germany GmbH

    Pancreatic Cancer

    phase 2 mab active

    1 trial

  13. XELOX combined with Fruquintinib and Sintilimab

    The First People's Hospital of Lianyungang

    Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  14. Xeloda 150 mg film-coated tablets, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELVORINE 100 mg/10 mL, solution injectable, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer

    phase 2 small molecule active

    1 trial

  15. Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  17. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  18. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  19. ZD6474

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    2 trials

  20. ZEULIDE 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée, Elacestrant

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  21. ZIMBERELIMAB

    Arcus Biosciences

    Pancreatic Cancer

    phase 2 small molecule on hold

    1 trial

  22. ZW25 (Zanidatamab)

    BEONE MEDICINES AUS PTY LTD

    HER2-amplified Biliary Tract Cancers

    phase 2 small molecule completed

    1 trial

  23. ZW25 (Zanidatamab)

    Jazz Pharmaceuticals Ireland Limited

    HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  24. ZW25 (Zanidatamab)

    Jazz Pharmaceuticals Ireland Limited

    HER2+/HR+ Breast Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources